Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shinichiro Takayanagi is active.

Publication


Featured researches published by Shinichiro Takayanagi.


Experimental Hematology | 2017

57R2A, a newly established monoclonal antibody against mouse GPR56, marks long-term repopulating hematopoietic stem cells

Yusuke Tokoro; Yoko Yamada; Shinichiro Takayanagi; Tetsuya Hagiwara

GPR56 molecule, a G-protein-coupled receptor, was suggested to be expressed in mouse hematopoietic stem cells (HSCs) by gene expression analyses. However, little is known about the cell surface expression of GPR56 protein in mouse HSCs due to the absence of an appropriate monoclonal antibody against GPR56 for flow cytometry analyses. In the present study, we established a novel monoclonal antibody against mouse GPR56 (57R2A) to examine the expression and distribution of GPR56 protein in HSCs. A flow cytometry analysis using 57R2A showed that GPR56 was highly expressed in the CD34-, c-Kit+, Sca-1+, lineage-negative (Lin-) fraction, which are highly enriched with HSCs. The competitive long-term repopulation (LTR) assay showed that LTR cells were included only within the GPR56+ fraction (≤15%) of bone marrow mononuclear cells (BMMNCs), but not within the remaining GPR56- fraction (85%), suggesting that all HSCs express GPR56 protein on their surface. Furthermore, we showed that double staining of BMMNCs with only 57R2A and AMM2 (monoclonal antibody against the HSC marker MPL) enabled enrichment of all LTR cells in the double-positive fraction (0.8% of BMMNCs), within which the LTR potency was consistent with the expression of both GPR56 and MPL. In conclusion, these findings for 57R2A suggest that all HSCs in mouse BMMNCs express GPR56 protein on their surface and that GPR56 is a positive marker for HSCs.


Archive | 2011

Anti-tim-3 antibody

Shinichiro Takayanagi; Hitomi Tomura; Tomonori Tawara; Yoshimasa Inagaki; Tsuguo Kubota; Koichi Akashi; Yoshikane Kikushige


Archive | 2010

Method for treatment of blood tumor using anti-tim-3 antibody

Shinichiro Takayanagi; 晋一郎 高柳; Yoshimasa Inagaki; 好昌 稲垣; Koichi Akashi; 浩一 赤司; Yoshikane Kikushige; 吉謙 菊繁


Archive | 2010

Anti-il-3rα antibody for use in treatment of blood tumor

Tomonori Tawara; Shinichiro Takayanagi; Yoshimasa Inagaki


Archive | 2013

Antibody to human il-3 receptor alpha chain

Tomonori Tawara; Shinichiro Takayanagi; Yoshimasa Inagaki


Blood | 2015

First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα

Tadakazu Akiyama; Shinichiro Takayanagi; Yoshimi Maekawa; Kohta Miyawaki; Fumiaki Jinnouchi; Takashi Jiromaru; Takeshi Sugio; Shinya Daitoku; Hirotake Kusumoto; Munetake Shimabe; Satoshi Nishikawa; Kengo Yamawaki; Kousuke Iijima; Masanori Hiura; Takeshi Takahashi; Yoshikane Kikushige; Hiromi Iwasaki; Koichi Akashi; Tomonori Tawara


Archive | 2016

Polynucleotide encoding antibody to human IL-3 receptor alpha chain

Tomonori Tawara; Shinichiro Takayanagi; Yoshimasa Inagaki


Archive | 2011

Anticorps anti-tim-3

Shinichiro Takayanagi; 晋一郎 高柳; Hitomi Tomura; ひとみ 戸村; Tomonori Tawara; 知紀 俵; Yoshimasa Inagaki; 好昌 稲垣; Tsuguo Kubota; 麗夫 久保田; Koichi Akashi; 浩一 赤司; Yoshikane Kikushige; 吉謙 菊繁


Archive | 2011

Anti-tim-3-antikörper

Shinichiro Takayanagi; Hitomi Tomura; Tomonori Tawara; Yoshimasa Inagaki; Tsuguo Kubota; Koichi Akashi; Yoshikane Kikushige


Archive | 2010

Interleukin-3 receptor alpha chain-binding antibody to treat leukemia

Tomonori Tawara; Shinichiro Takayanagi; Yoshimasa Inagaki

Collaboration


Dive into the Shinichiro Takayanagi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge